What Message Is the Helmsman Change of CFDA Transmitting?
2015/2/1 E药经理人

     CFDA now has a new leader. His name is Bi Jingquan whose latest title was the State Council deputy secretary general. Confirmed by the source, on 26th, January, CFDA has announced this appointment in an inside-scale meeting.

     On 27th, January, we have confirmed with several sources that CFDA now has a new helmsman. In the afternoon of 26, CFDA announced that Bi Jingquan became director general of CFDA in its inside-scale meeting.

     Before Bi got assigned with this new job, he worked as the State Council deputy secretary general for seven years. When this appointment takes effect, Zhang Yong who worked as the CFDA director general for only two years will leave for a new position in National Development and Reform Commission (NDRC) as its deputy director according the source.

     There is always a big deal when the personnel change happens in CFDA and this time comes the biggest. So what will this new leader bring to CFDA? Where will this man lead CFDA to? Does this appointment indicate a more active cooperation between the National Health and Family Planning Commission and the NDRC since Bi has been working in NDRC for thirty years?

     After this appointment hit the public, there have been three most accepted interpretations outside.

     No.1

     Bi joined NDRC in 1984 and since then his job has always been related to the price regulation. According to the public materials, he proposed that producer price be printed on the external package which in his opinion will help clear the price issues. He also commented that the drug reimbursement policy should be based on the price of generic drugs and the expense of the patent drug above this standard should be paid by the patients themselves.

     No.2

     As one of the crucial departments related to the wellbeing of China and Chinese people, CFDA has been unreasonably slow on the drug approval and on solving problems like that. So a new leader is needed for the reform to proceed. There are voices that Zhang has been real tough on the implementations of supervision regulations but China’s drug management has seen little changes under his administration.

     No.3

     Since the beginning of 2014, the personnel changes on the management level of CFDA is unprecedentedly accelerating. In the past two years, on the website of CFDA, almost 200 personnel changes were announced. Some of them were listed at the same day. For example, on June, 5th, 2013, 41 CFDA officers got transferred from their original positions.

    http://www.duyihua.cn
返回 E药经理人 返回首页 返回百拇医药